Michael joined CTTC in July 2024 and is responsible for commercializing life science technologies arising from the Warren Center for Neuroscience Drug Development. Prior to joining CTTC, Michael worked for the Office of Entrepreneurship and Innovation Partnerships at Binghamton University, where he was responsible for evaluating new technology disclosures, contributing to patent prosecution efforts, and marketing life science technologies to potential licensees.
Michael received his BS in Integrative Neuroscience and Biochemistry in 2019 and later completed a MS in Pharmaceutical Sciences from Binghamton University. During this time, he studied levodopa-induced dyskinesia in Parkinson’s disease in the lab, enrolled in the national NSF I-Corps program, and spin out a start-up company to advance novel treatments for this condition.
